Antibodies Against "Human" Biopharmaceuticals: Individualized Therapy with TNF-alpha Inhibitors Guided by Immunopharmacologic Assessments

Autoantibodies: Third Edition

Volumn , Issue , 2013, Pages 803-816

  Steenholdt, Casper ^a   Bendtzen, Klaus ^b  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b University of Copenhagen   (Denmark)

Author keywords

Anti TNF antibodies; Bioavailability; Immunogenicity; Inflammatory bowel diseases; Pharmacodynamics; Pharmacokinetics; Recombinant protein therapeutics; Rheumatoid arthritis; Theranostics

Indexed keywords

EID: 84902068858     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-444-56378-1.00093-9     Document Type: Chapter

References (10)

1. Aikawa N.E., de Carvalho J.F., Silva C.A.A., Bonfa E. Immunogenicity of anti-TNF-alpha agents in autoimmune diseases. Clin Rev Allergy Immunol 2010, 38:82-89.
2. Allez M., Karmiris K., Louis E., Van Assche G., Ben-Horin S., Klein A., et al. Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects. J Crohn's Colitis 2010, 4:355-366.
3. Furst D.E., Keystone E.C., Braun J., Breedveld F.C., Burmester G.R., De Benedetti F., et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2010. Ann Rheum Dis 2011, 70(Suppl. 1):i2-36.
4. Bendtzen K., Ainsworth M., Steenholdt C., Thomsen O.O., Brynskov J. Individual medicine in inflammatory bowel disease: monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies. Scand J Gastroenterol 2009, 44:774-781.
5. Wolbink G.J., Aarden L.A., Dijkmans B.A. Dealing with immunogenicity of biologicals: assessment and clinical relevance. Curr Opin Rheumatol 2009, 21:211-215.
6. Ordas I., Mould D.R., Feagan B.G., Sandborn W.J. Anti-TNF monoclonal antibodies in inflammatory bowel disease: pharmacokinetics-based dosing paradigms. Clin Pharmacol Ther 2012, 91:635-646.
7. Bendtzen K. Anti-TNF-α biotherapies: perspectives for evidence-based personalized medicine. Immunotherapy 2012, 4:1167-1179.
8. Krieckaert C., Rispens T., Wolbink G. Immunogenicity of biological therapeutics: from assay to patient. Curr Opin Rheumatol 2012, 24:306-311.
9. Chaparro M., Guerra I., Munoz-Linares P., Gisbert J.P. Systematic review: antibodies and anti-TNF-alpha levels in inflammatory bowel disease. Aliment Pharmacol Ther 2012, 35:971-986.
10. Yanai H., Hanauer S.B. Assessing response and loss of response to biological therapies in IBD. Am J Gastroenterol 2011, 106:685-698.